U.S., Aug. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07096193) titled 'Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus' on July 24.
Brief Summary: The goals of this clinical study are to first learn more about safety and dosing of the study drug GS-4321 in healthy participants. The study will then learn about the safety and effectiveness of GS-4321 in participants with chronic hepatitis delta (CHD).
The primary objective of Phase 1 of this study to evaluate the safety, tolerability and Pharmacokinetics (PK) of the escalating single doses of GS-4321 administered in healthy participants.
The primary objective of Phase 2 of this study is to evaluate the effica...